Conference will be held October 29-31 at the Palace Hotel, San Francisco
NEW YORK, Oct. 24 /PRNewswire/ -- Gerson Lehrman Group, the world's
marketplace for expertise, and the Biotechnology Industry Organization
(BIO) have set the scientific agenda for the Seventh Annual BIO Investor
Forum. Featured therapeutic panels will include some of Gerson Lehrman
Group's leading physician consultants along with executives from public and
private equity biotechnology companies to discuss:
-- Congestive Heart Failure
-- Cystic Fibrosis
-- Lung Cancer
-- Neurodegenerative Diseases
-- Novel Solid Tumor Targets
-- Pre-ASH Primer
"With the financial markets experiencing an unprecedented level of volatility, investment professionals place a greater premium than ever before on sophisticated expertise to guide their decision-making," said Alexander Saint-Amand, President and Chief Executive Officer of Gerson Lehrman Group. "In the healthcare and biotechnology sectors, highly focused and unbiased education plays a critical role; the BIO Investor Forum brings together the three populations relevant to fully understand how to maneuver in this market: industry executives, sophisticated investors, and the world's top clinical thought leaders."
Through this partnership, BIO tapped Gerson Lehrman Group's network of more than 200,000 experts from around the world to identify clinicians and researchers to serve as panel speakers during the conference. The speakers were specifically identified to focus on some of the most interesting and novel development areas within the biotechnology industry, and represent some of the top clinical minds in their respective fields.
"This year's panel topics focus on disease areas in which we expect innovative new therapies to produce significant clinical advances, representing attractive investment and partnering opportunities," said Jim Greenwood, President and Chief Executive Officer of BIO. "Working with Gerson Lehrman Group allows BIO to provide the independent scientific and clinical expertise to offer outstanding Therapeutic Workshop panels for our investor and emerging company attendees."
The Seventh Annual BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture and private equity investors, buy-side investors and research analysts. In addition, the Seventh Annual BIO Investor Forum draws business development executives from leading global pharmaceutical and mature biotechnology companies.
To see the latest updates to 2008 programming and speakers for the Seventh Annual BIO Investor Forum, please visit http://investorforum.bio.org/bif/2008/TW.html.
About Gerson Lehrman Group
Gerson Lehrman Group provides technology and services to support a marketplace for expertise. Since 1998, its platform for consultation and collaboration has helped the world's leading financial services firms, consultancies, corporations, and nonprofits find, engage, and manage experts in a broad range of industries and disciplines. Gerson Lehrman Group's unparalleled network of the world's leading expert consultants, known as the Gerson Lehrman Group Councils, includes more than 200,000 subject-matter experts who educate and provide insight to decision makers through a wide range of consulting methods, including telephone consultations, expert surveys, and seminars. Gerson Lehrman Group has invested in one of the world's most sophisticated infrastructures for expert recruiting and compliance. For more information about Gerson Lehrman Group, please visit http://www.glgroup.com.
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Gerson Lehrman Group and the Gerson Lehrman Group logo are registered
trademarks of Gerson Lehrman Group [in the United States and other
countries]. Failure to list any other Gerson Lehrman Group trademarks does
not constitute a waiver of any rights to any Gerson Lehrman Group
trademarks, including unregistered trademarks. Other names included in this
press release may also be the registered or unregistered trademarks of
their respective owners.
Gerson Lehrman Group Contact:
Biotechnology Industry Organization Contact:
John Craighead, Ph.D.
|SOURCE Gerson Lehrman Group|
Copyright©2008 PR Newswire.
All rights reserved